Myovant Sciences (NYSE:MYOV) Now Covered by Analysts at Svb Leerink

Share on StockTwits

Svb Leerink began coverage on shares of Myovant Sciences (NYSE:MYOV) in a report published on Monday morning, BenzingaRatingsTable reports. The firm issued an outperform rating and a $26.00 target price on the stock.

MYOV has been the topic of a number of other reports. Zacks Investment Research raised Myovant Sciences from a hold rating to a buy rating and set a $8.25 price objective on the stock in a research note on Saturday, August 10th. ValuEngine raised Myovant Sciences from a hold rating to a buy rating in a research note on Thursday, August 1st. Citigroup started coverage on Myovant Sciences in a research note on Thursday, May 30th. They issued a buy rating and a $25.00 price objective on the stock. Finally, Leerink Swann started coverage on Myovant Sciences in a research note on Monday. They issued an outperform rating and a $26.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Myovant Sciences has an average rating of Buy and a consensus price target of $24.91.

NYSE MYOV opened at $7.93 on Monday. The business’s 50-day moving average price is $7.84 and its two-hundred day moving average price is $15.01. Myovant Sciences has a 12 month low of $6.60 and a 12 month high of $27.45. The firm has a market capitalization of $627.36 million, a PE ratio of -1.94 and a beta of 1.05. The company has a current ratio of 3.42, a quick ratio of 3.42 and a debt-to-equity ratio of 1.24.

Myovant Sciences (NYSE:MYOV) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.06. As a group, analysts forecast that Myovant Sciences will post -3.03 earnings per share for the current fiscal year.

In related news, major shareholder Andrew Lo acquired 2,424,242 shares of the stock in a transaction dated Tuesday, June 4th. The stock was purchased at an average cost of $8.25 per share, with a total value of $19,999,996.50. Following the completion of the purchase, the insider now directly owns 40,765,599 shares in the company, valued at approximately $336,316,191.75. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Kathleen Sebelius acquired 5,000 shares of the stock in a transaction dated Wednesday, June 12th. The stock was bought at an average cost of $8.96 per share, with a total value of $44,800.00. Following the completion of the purchase, the director now owns 100 shares of the company’s stock, valued at $896. The disclosure for this purchase can be found here. Over the last three months, insiders bought 2,437,242 shares of company stock valued at $20,117,597. Company insiders own 3.00% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Norges Bank bought a new position in Myovant Sciences in the fourth quarter valued at about $12,308,000. Victory Capital Management Inc. bought a new position in Myovant Sciences in the first quarter valued at about $20,104,000. BlackRock Inc. boosted its holdings in Myovant Sciences by 5.2% in the fourth quarter. BlackRock Inc. now owns 27,912 shares of the company’s stock valued at $458,000 after acquiring an additional 1,386 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Myovant Sciences by 73.6% in the second quarter. Janus Henderson Group PLC now owns 4,350,335 shares of the company’s stock valued at $39,371,000 after acquiring an additional 1,843,943 shares during the last quarter. Finally, First Manhattan Co. boosted its holdings in Myovant Sciences by 2,146.6% during the second quarter. First Manhattan Co. now owns 400,000 shares of the company’s stock worth $3,620,000 after buying an additional 382,195 shares during the last quarter. 26.79% of the stock is owned by institutional investors.

About Myovant Sciences

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Read More: Why do companies pay special dividends?

Analyst Recommendations for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Civic  Market Cap Achieves $26.92 Million
Civic Market Cap Achieves $26.92 Million
TRAXIA Tops 24-Hour Trading Volume of $207.00
TRAXIA Tops 24-Hour Trading Volume of $207.00
TOP  Price Hits $0.0022
TOP Price Hits $0.0022
Syndax Pharmaceuticals  Stock Rating Upgraded by Zacks Investment Research
Syndax Pharmaceuticals Stock Rating Upgraded by Zacks Investment Research
Laboratory Corp. of America  Stock Rating Upgraded by Zacks Investment Research
Laboratory Corp. of America Stock Rating Upgraded by Zacks Investment Research
Renewable Energy Group  Rating Increased to Hold at Zacks Investment Research
Renewable Energy Group Rating Increased to Hold at Zacks Investment Research


 
© 2006-2019 Zolmax.